TrialThe New England journal of medicine2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Sandra M Swain et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,041 papers cite itlatest 60 shown
this paperpooled ittrialcites it